Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade.
PD-L1
biomarkers
immune checkpoint inhibitors
liquid biopsy
lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
14
05
2021
revised:
17
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Checkpoint inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients demonstrate a durable clinical response. PD-L1 scoring is currently the only biomarker measure routinely used to select patients for immunotherapy, but its predictive accuracy is modest. The aim of our study was to evaluate a proteomic assay for the analysis of patient plasma in the context of immunotherapy. Pretreatment plasma samples from 43 NSCLC patients who received anti-PD-(L)1 therapy were analyzed using a proximity extension assay (PEA) to quantify 92 different immune oncology-related proteins. The plasma protein levels were associated with clinical and histopathological parameters, as well as therapy response and survival. Unsupervised hierarchical cluster analysis revealed two patient groups with distinct protein profiles associated with high and low immune protein levels, designated as "hot" and "cold". Further supervised cluster analysis based on T-cell activation markers showed that higher levels of T-cell activation markers were associated with longer progression-free survival (PFS) (
Identifiants
pubmed: 34206510
pii: cancers13133116
doi: 10.3390/cancers13133116
pmc: PMC8268315
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sjöberg Foundation
ID : #1
Organisme : Cancerfonden
ID : CAN2015/709 and CAN2018/816
Références
Clin Lung Cancer. 2019 Jul;20(4):258-262.e1
pubmed: 30926355
BMC Cancer. 2019 Jul 29;19(1):741
pubmed: 31357969
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Ann Oncol. 2017 Aug 1;28(8):1988-1995
pubmed: 28595336
Ther Drug Monit. 2018 Feb;40(1):9-16
pubmed: 29084031
J Immunother Cancer. 2018 Nov 23;6(1):129
pubmed: 30470260
Mod Pathol. 2017 Oct;30(10):1411-1421
pubmed: 28664936
Cell. 2020 Apr 30;181(3):674-687.e13
pubmed: 32298652
Cancers (Basel). 2020 Oct 14;12(10):
pubmed: 33066479
Cancer Lett. 2013 May 28;332(2):133-40
pubmed: 20817393
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
BMC Med. 2018 Oct 2;16(1):166
pubmed: 30285732
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Immune Netw. 2020 May 20;20(3):e27
pubmed: 32655975
J Immunol. 2007 Feb 15;178(4):2278-86
pubmed: 17277133
Cancer Immunol Immunother. 2001 Dec;50(10):533-8
pubmed: 11776375
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918661
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Proc Natl Acad Sci U S A. 1990 Jul;87(14):5238-42
pubmed: 2115167
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Pain Symptom Manage. 2015 Feb;49(2):258-64
pubmed: 24996034
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancers (Basel). 2020 Dec 02;12(12):
pubmed: 33276569
J Immunother Cancer. 2019 Mar 21;7(1):82
pubmed: 30898149
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918147
Lung Cancer (Auckl). 2018 Jan 03;9:1-11
pubmed: 29379323
Cancer Cell. 2020 Nov 9;38(5):624-625
pubmed: 33171127
Oncoimmunology. 2016 Sep 9;5(12):e1232222
pubmed: 28123870
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Oncoimmunology. 2015 Dec 3;5(3):e1108515
pubmed: 27141365
Clin Cancer Res. 2020 Jan 15;26(2):487-504
pubmed: 31636098
Oncoimmunology. 2020 Jun 16;9(1):1774314
pubmed: 32923134
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Clin Biochem. 2005 Oct;38(10):887-91
pubmed: 16054616
Oncoimmunology. 2020 Oct 27;9(1):1832348
pubmed: 33178494
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Curr Drug Targets. 2012 Jun;13(6):842-62
pubmed: 22250650